RhumbLine Advisers
HCAT icon

RhumbLine Advisers’s Health Catalyst HCAT Stock Holding History

RhumbLine Advisers’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$109K Sell
85,596
-4,459
-5% -$8.39K ﹤0.01% 3373
2025
Q4 		$215K Sell
90,055
-6,801
-7% -$18.6K ﹤0.01% 3151
2025
Q3 		$276K Sell
96,856
-5,130
-5% -$17.6K ﹤0.01% 3051
2025
Q2 		$384K Buy
101,986
+12,127
+13% +$47.7K ﹤0.01% 2848
2025
Q1 		$407K Sell
89,859
-582
-0.6% -$3.08K ﹤0.01% 2704
2024
Q4 		$639K Buy
90,441
+1,042
+1% +$8.3K ﹤0.01% 2507
2024
Q3 		$728K Sell
89,399
-1,712
-2% -$12.4K ﹤0.01% 2453
2024
Q2 		$582K Buy
91,111
+7,589
+9% +$48.7K ﹤0.01% 2562
2024
Q1 		$629K Buy
83,522
+1,643
+2% +$15K ﹤0.01% 2521
2023
Q4 		$758K Buy
81,879
+23
+0% +$188 ﹤0.01% 2421
2023
Q3 		$828K Buy
81,856
+3,865
+5% +$46.1K ﹤0.01% 2313
2023
Q2 		$975K Sell
77,991
-9,618
-11% -$115K ﹤0.01% 2304
2023
Q1 		$1.02M Sell
87,609
-13,263
-13% -$169K ﹤0.01% 2108
2022
Q4 		$1.07M Buy
100,872
+18,680
+23% +$180K ﹤0.01% 2096
2022
Q3 		$797K Buy
82,192
+5,330
+7% +$70.6K ﹤0.01% 2265
2022
Q2 		$1.11M Buy
76,862
+23,673
+45% +$404K ﹤0.01% 2085
2022
Q1 		$1.39M Buy
53,189
+4,094
+8% +$116K ﹤0.01% 1992
2021
Q4 		$1.95M Buy
49,095
+409
+0.8% +$18.6K ﹤0.01% 1901
2021
Q3 		$2.44M Buy
48,686
+5,070
+12% +$277K ﹤0.01% 1792
2021
Q2 		$2.42M Buy
43,616
+7,133
+20% +$380K ﹤0.01% 1854
2021
Q1 		$1.71M Sell
36,483
-3,837
-10% -$186K ﹤0.01% 1980
2020
Q4 		$1.75M Buy
40,320
+982
+2% +$36.2K ﹤0.01% 1912
2020
Q3 		$1.44M Sell
39,338
-5,110
-11% -$174K ﹤0.01% 1848
2020
Q2 		$1.3M Buy
44,448
+21,423
+93% +$592K ﹤0.01% 1937
2020
Q1 		$602K Buy
23,025
+15,418
+203% +$471K ﹤0.01% 2099
2019
Q4 		$264K Buy
7,607
+261
+4% +$8.64K ﹤0.01% 2651
2019
Q3 		$232K Buy
+7,346
New +$289K ﹤0.01% 2692

Other funds holding HCAT

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RhumbLine Advisers's HCAT Position: Q1 2026 in Review

RhumbLine Advisers reduced its Health Catalyst (HCAT) stake by 5% in Q1 2026, selling an estimated $8.39K and leaving 85,596 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #3373.

RhumbLine Advisers first reported a position in HCAT in Q3 2019 and has held it in 27 quarters since. The position peaked at $2.44M in Q3 2021. 130 funds tracked by Wall St. Rank hold HCAT as of Q1 2026.

  • RhumbLine Advisers held 85,596 shares of Health Catalyst worth $109K as of Q1 2026.
  • RhumbLine Advisers sold 4,459 Health Catalyst shares in Q1 2026, an estimated $8.39K.
  • Health Catalyst made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3373 holding.
  • RhumbLine Advisers first reported a position in Health Catalyst in Q3 2019 and has held it in 27 quarters since.
  • RhumbLine Advisers's Health Catalyst position peaked at $2.44M in Q3 2021.
  • 130 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.